Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria

Although various types of mRNA-based vaccines have been explored, the optimal conditions for induction of both humoral and cellular immunity remain rather unknown. In this study, mRNA vaccines of nucleoside-modified mRNA in lipoplexes (LPXs) or lipid nanoparticles (LNPs) were evaluated after administration in mice through different routes, assessing mRNA delivery, tolerability and immunogenicity. In addition, we investigated whether mRNA vaccines could benefit from the inclusion of the adjuvant alpha-galactosylceramide (αGC), an invariant Natural Killer T (iNKT) cell ligand. Intramuscular (IM) vaccination with ovalbumin (OVA)-encoding mRNA encapsulated in LNPs adjuvanted with αGC showed the highest antibody- and CD8+ T cell responses. Furthermore, we observed that addition of signal peptides and endocytic sorting signals of either LAMP1 or HLA-B7 in the OVA-encoding mRNA sequence further enhanced CD8+ T cell activation although reducing the induction of IgG antibody responses. Moreover, mRNA LNPs with the ionizable lipidoid C12-200 exhibited higher pro-inflammatory- and reactogenic activity compared to mRNA LNPs with SM-102, correlating with increased T cell activation and antitumor potential. We also observed that αGC could further enhance the cellular immunity of clinically relevant mRNA LNP vaccines, thereby promoting therapeutic antitumor potential. Finally, a Listeria monocytogenes mRNA LNP vaccine supplemented with αGC showed synergistic protective effects against listeriosis, highlighting a key advantage of co-activating iNKT cells in antibacterial mRNA vaccines. Taken together, our study offers multiple insights for optimizing the design of mRNA vaccines for disease applications, such as cancer and intracellular bacterial infections.

Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer

Throughout the last decades, mRNA vaccines have been developed as a cancer immunotherapeutic and the technology recently gained momentum during the COVID-19 pandemic. Recent promising results obtained from clinical trials investigating lipid-based mRNA vaccines in cancer therapy further highlighted the potential of this therapy. Interestingly, while the technologies being used in authorized mRNA vaccines for the prevention of COVID-19 are relatively similar, mRNA vaccines in clinical development for cancer vaccination show marked differences in mRNA modification, lipid carrier, and administration route. In this review, we describe findings on how these factors can impact the potency of mRNA vaccines in cancer therapy and provide insights into the complex interplay between them. We discuss how lipid carrier composition can affect passive targeting to immune cells to improve the efficacy and safety of mRNA vaccines. Finally, we summarize strategies that are established or still being explored to improve the efficacy of mRNA cancer vaccines and include next-generation vaccines that are on the horizon in clinical development.

Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium

The therapeutic potential of liposomes to deliver drugs into inflamed tissue is well documented. Liposomes are believed to largely transport drugs into inflamed joints by selective extravasation through endothelial gaps at the inflammatory sites, known as the enhanced permeation and retention effect. However, the potential of blood-circulating myeloid cells for the uptake and delivery of liposomes has been largely overlooked. Here we show that myeloid cells can transport liposomes to inflammatory sites in a collagen-induced arthritis model. It is shown that the selective depletion of the circulating myeloid cells reduces the accumulation of liposomes up to 50-60%, suggesting that myeloid-cell-mediated transport accounts for more than half of liposomal accumulation in inflamed regions. Although it is widely believed that PEGylation inhibits premature liposome clearance by the mononuclear phagocytic system, our data show that the long blood circulation times of PEGylated liposomes rather favours uptake by myeloid cells. This challenges the prevailing theory that synovial liposomal accumulation is primarily due to the enhanced permeation and retention effect and highlights the potential for other pathways of delivery in inflammatory diseases.

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine

Rationale: Although promising responses are obtained in patients treated with immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) and its receptor programmed death-1 (PD-1), only a fraction of patients benefits from this immunotherapy. Cancer vaccination may be an effective approach to improve the response to immune checkpoint inhibitors anti-PD-L1/PD-1 therapy. However, there is a lack of research on the dynamics of PD-L1 expression in response to cancer vaccination. Methods: We performed non-invasive whole-body imaging to visualize PD-L1 expression at different timepoints after vaccination of melanoma-bearing mice. Mice bearing ovalbumin (OVA) expressing B16 tumors were i.v. injected with the Galsome mRNA vaccine: OVA encoding mRNA lipoplexes co-encapsulating a low or a high dose of the atypical adjuvant α-galactosylceramide (αGC) to activate invariant natural killer T (iNKT) cells. Serial non-invasive whole-body immune imaging was performed using a technetium-99m (99mTc)-labeled anti-PD-L1 nanobody, single-photon emission computerized tomography (SPECT) and X-ray computed tomography (CT) images were quantified. Additionally, cellular expression of PD-L1 was evaluated with flow cytometry. Results: SPECT/CT-imaging showed a rapid and systemic upregulation of PD-L1 after vaccination. PD-L1 expression could not be correlated to the αGC-dose, although we observed a dose-dependent iNKT cell activation. Dynamics of PD-L1 expression were organ-dependent and most pronounced in lungs and liver, organs to which the vaccine was distributed. PD-L1 expression in lungs increased immediately after vaccination and gradually decreased over time, whereas in liver, vaccination-induced PD-L1 upregulation was short-lived. Flow cytometric analysis of these organs further showed myeloid cells as well as non-immune cells with elevated PD-L1 expression in response to vaccination. SPECT/CT imaging of the tumor demonstrated that the expression of PD-L1 remained stable over time and was overall not affected by vaccination although flow cytometric analysis at the cellular level demonstrated changes in PD-L1 expression in various immune cell populations following vaccination. Conclusion: Repeated non-invasive whole-body imaging using 99mTc-labeled anti-PD-L1 nanobodies allows to document the dynamic nature of PD-L1 expression upon vaccination. Galsome vaccination rapidly induced systemic upregulation of PD-L1 expression with the most pronounced upregulation in lungs and liver while flow cytometry analysis showed upregulation of PD-L1 in the tumor microenvironment. This study shows that imaging using nanobodies may be useful for monitoring vaccine-mediated PD-L1 modulation in patients and could provide a rationale for combination therapy. To the best of our knowledge, this is the first report that visualizes PD-L1 expression upon cancer vaccination.

Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures

Messenger RNA (mRNA) lipid nanoparticles (LNPs) have emerged at the forefront during the COVID-19 vaccination campaign. Despite their tremendous success, mRNA vaccines currently require storage at deep freeze temperatures which complicates their storage and distribution, and ultimately leads to lower accessibility to low- and middle-income countries. To elaborate on this challenge, we investigated freeze-drying as a method to enable storage of mRNA LNPs at room- and even higher temperatures. More specifically, we explored a novel continuous freeze-drying technique based on spin-freezing, which has several advantages compared to classical batch freeze-drying including a much shorter drying time and improved process and product quality controlling. Here, we give insight into the variables that play a role during freeze-drying by evaluating the impact of the buffer and mRNA LNP formulation (ionizable lipid to mRNA weight ratio) on properties such as size, morphology and mRNA encapsulation. We found that a sufficiently high ionizable lipid to mRNA weight ratio was necessary to prevent leakage of mRNA during freeze-drying and that phosphate and Tris, but not PBS, were appropriate buffers for lyophilization of mRNA LNPs. We also studied the stability of optimally lyophilized mRNA LNPs at 4 °C, 22 °C, and 37 °C and found that transfection properties of lyophilized mRNA LNPs were maintained during at least 12 weeks. To our knowledge, this is the first study that demonstrates that optimally lyophilized mRNA LNPs can be safely stored at higher temperatures for months without losing their transfection properties.

Innate immune mechanisms of mRNA vaccines

The lipid nanoparticle (LNP)-encapsulated, nucleoside-modified mRNA platform has been used to generate safe and effective vaccines in record time against COVID-19. Here, we review the current understanding of the manner whereby mRNA vaccines induce innate immune activation and how this contributes to protective immunity. We discuss innate immune sensing of mRNA vaccines at the cellular and intracellular levels and consider the contribution of both the mRNA and the LNP components to their immunogenicity. A key message that is emerging from recent observations is that the LNP carrier acts as a powerful adjuvant for this novel vaccine platform. In this context, we highlight important gaps in understanding and discuss how new insight into the mechanisms underlying the effectiveness of mRNA-LNP vaccines may enable tailoring mRNA and carrier molecules to develop vaccines with greater effectiveness and milder adverse events in the future.

Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies

In this brief perspective, we describe key events in the history of the lipid-based nanomedicine field, highlight Canadian contributions, and outline areas where lipid nanoparticle technology is poised to have a transformative effect on the future of medicine.

Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

The recent approval of messenger RNA (mRNA)-based vaccines to combat the SARS-CoV-2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA (saRNA) as a flexible immunotherapy platform to treat infectious diseases. Besides the antigen it encodes, mRNA itself has an immune-stimulating activity that can contribute to vaccine efficacy. This self-adjuvant effect, however, will interfere with mRNA translation and may influence the desired therapeutic outcome. To further exploit its potential as a versatile therapeutic platform, it will be crucial to control mRNA's innate immune-stimulating properties. In this regard, we describe the mechanisms behind the innate immune recognition of mRNA and provide an extensive overview of strategies to control its innate immune-stimulating activity. These strategies range from modifications to the mRNA backbone itself, optimization of production and purification processes to the combination with innate immune inhibitors. Furthermore, we discuss the delicate balance of the self-adjuvant effect in mRNA vaccination strategies, which can be both beneficial and detrimental to the therapeutic outcome.

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP product stability. Analysis of mRNA-LNP structures reveals that mRNA, the ionizable cationic lipid and water are present in the LNP core. The neutral helper lipids are mainly positioned in the outer, encapsulating, wall. mRNA hydrolysis is the determining factor for mRNA-LNP instability. It is currently unclear how water in the LNP core interacts with the mRNA and to what extent the degradation prone sites of mRNA are protected through a coat of ionizable cationic lipids. To improve the stability of mRNA-LNP vaccines, optimization of the mRNA nucleotide composition should be prioritized. Secondly, a better understanding of the milieu the mRNA is exposed to in the core of LNPs may help to rationalize adjustments to the LNP structure to preserve mRNA integrity. Moreover, drying techniques, such as lyophilization, are promising options still to be explored.

The dawn of mRNA vaccines: The COVID-19 case

In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new class of vaccine products, which consist of synthetic mRNA strands encoding the SARS-CoV-2 Spike glycoprotein, packaged in lipid nanoparticles to deliver mRNA to cells. This review digs deeper into the scientific breakthroughs of the last decades that laid the foundations for the rapid rise of mRNA vaccines during the COVID-19 pandemic. As well as providing momentum for mRNA vaccines, SARS-CoV-2 represents an ideal case study allowing to compare design-activity differences between the different mRNA vaccine candidates. Therefore, a detailed overview of the composition and (pre)clinical performance of the three most advanced mRNA vaccines is provided and the influence of choices in their structural design on to their immunogenicity and reactogenicity profile is discussed in depth. In addition to the new fundamental insights in the mRNA vaccines' mode of action highlighted here, we also point out which unknowns remain that require further investigation and possibly, optimization in future mRNA vaccine development.

mRNA in cancer immunotherapy: beyond a source of antigen

mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its many advantages have paved the path beyond this application. In addition, due to smart design of both the structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability and selective targeting, the therapeutic potential of mRNA can be considered as endless.As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a rationale for their clinical application.

Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation

Efficient and safe cell engineering by transfection of nucleic acids remains one of the long-standing hurdles for fundamental biomedical research and many new therapeutic applications, such as CAR T cell-based therapies. mRNA has recently gained increasing attention as a more safe and versatile alternative tool over viral- or DNA transposon-based approaches for the generation of adoptive T cells. However, limitations associated with existing nonviral mRNA delivery approaches hamper progress on genetic engineering of these hard-to-transfect immune cells. In this study, we demonstrate that gold nanoparticle-mediated vapor nanobubble (VNB) photoporation is a promising upcoming physical transfection method capable of delivering mRNA in both adherent and suspension cells. Initial transfection experiments on HeLa cells showed the importance of transfection buffer and cargo concentration, while the technology was furthermore shown to be effective for mRNA delivery in Jurkat T cells with transfection efficiencies up to 45%. Importantly, compared to electroporation, which is the reference technology for nonviral transfection of T cells, a fivefold increase in the number of transfected viable Jurkat T cells was observed. Altogether, our results point toward the use of VNB photoporation as a more gentle and efficient technology for intracellular mRNA delivery in adherent and suspension cells, with promising potential for the future engineering of cells in therapeutic and fundamental research applications.

mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice

To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant reduction of the inflammatory responses. Thanks to this, mRNA therapeutics have entered the field of passive immunization. Here, we established an mRNA treatment that is based on mRNA that codes for a bispecific single-domain antibody construct that can selectively recruit innate immune cells to cells infected with influenza A virus. The constructs consist of a single-domain antibody that binds to the ectodomain of the conserved influenza A matrix protein 2, while the other single-domain antibody binds to the activating mouse Fcγ receptor IV. Formulating the mRNA into DOTAP (1,2-dioleoyl-3-trimethylammonium-propane)/cholesterol nanoparticles and delivering these intratracheally to mice allowed the production of the bispecific single-domain antibody in the lungs, and administration of these mRNA-particles prior to influenza A virus infection was associated with a significant reduction in viral titers and a reduced morbidity in mice. Overall, our data provide evidence that the local delivery of mRNA encoding a bispecific single-domain antibody format in the lungs could be a promising pulmonary antiviral prophylactic treatment.

Longitudinal In Vivo Assessment of Host-Microbe Interactions in a Murine Model of Pulmonary Aspergillosis

The fungus Aspergillus fumigatus is ubiquitous in nature and the most common cause of invasive pulmonary aspergillosis (IPA) in patients with a compromised immune system. The development of IPA in patients under immunosuppressive treatment or in patients with primary immunodeficiency demonstrates the importance of the host immune response in controlling aspergillosis. However, study of the host-microbe interaction has been hampered by the lack of tools for their non-invasive assessment. We developed a methodology to study the response of the host's immune system against IPA longitudinally in vivo by using fluorine-19 magnetic resonance imaging (¹⁹F MRI). We showed the advantage of a perfluorocarbon-based contrast agent for the in vivo labeling of macrophages and dendritic cells, permitting quantification of pulmonary inflammation in different murine IPA models. Our findings reveal the potential of ¹⁹F MRI for the assessment of rapid kinetics of innate immune response against IPA and the permissive niche generated through immunosuppression.

Tri-modal In vivo Imaging of Pancreatic Islets Transplanted Subcutaneously in Mice

PURPOSE

Transplantation of pancreatic islets (PIs) is a promising therapeutic approach for type 1 diabetes. The main obstacle for this strategy is that the outcome of islet engraftment depends on the engraftment site. It was our aim to develop a strategy for using non-invasive imaging techniques to assess the location and fate of transplanted PIs longitudinally in vivo.

PROCEDURES

In order to overcome the limitations of individual imaging techniques and cross-validate findings by different modalities, we have combined fluorine magnetic resonance imaging (F-19 MRI), fluorescence imaging (FLI), and bioluminescent imaging (BLI) for studying subcutaneously transplanted PIs and beta cell-like cells (INS-1E cell line) in vivo. We optimized the transduction (using lentiviral vectors) and labeling procedures (using perfluoro crown ether nanoparticles with a fluorescence dye) for PIs and INS-1E cell imaging.

RESULTS

The feasibility of using the proposed imaging methods for PI assessment was demonstrated both in vitro and in vivo. Our data suggested that F-19 MRI is suitable for high-resolution localization of transplanted cells and PIs; FLI is essential for confirmation of contrast localization by histology; and BLI is a reliable method to assess cell viability and survival after transplantation. No significant side effects on cell viability and function have been observed.

CONCLUSIONS

The proposed tri-modal imaging platform is a valuable approach for the assessment of engrafted PIs in vivo. It is potentially suitable for comparing different transplantation sites and evaluating novel strategies for improving PI transplantation technique in the future.

Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells

Messenger RNA encoding tumor antigens has the potential to evoke effective antitumor immunity. This study reports on a nanoparticle platform, named mRNA Galsomes, that successfully co-delivers nucleoside-modified antigen-encoding mRNA and the glycolipid antigen and immunopotentiator α-galactosylceramide (α-GC) to antigen-presenting cells after intravenous administration. By co-formulating low doses of α-GC, mRNA Galsomes induce a pluripotent innate and adaptive tumor-specific immune response in mice, with invariant natural killer T cells (iNKT) as a driving force. In comparison, mRNA Galsomes exhibit advantages over the state-of-the-art cancer vaccines using unmodified ovalbumin (OVA)-encoding mRNA, as we observed up to seven times more tumor-infiltrating antigen-specific cytotoxic T cells, combined with a strong iNKT cell and NK cell activation. In addition, the presence of suppressive myeloid cells (myeloid-derived suppressor cells and tumor-associated macrophages) in the tumor microenvironment was significantly lowered. Owing to these antitumor effects, OVA mRNA Galsomes significantly reduced tumor growth in established E.G7-OVA lymphoma, with a complete tumor rejection in 40% of the animals. Moreover, therapeutic vaccination with mRNA Galsomes enhanced the responsiveness to treatment with a PD-L1 checkpoint inhibitor in B16-OVA melanoma, as evidenced by a synergistic reduction of tumor outgrowth and a significantly prolonged median survival. Taken together, these data show that intravenously administered mRNA Galsomes can provide controllable, multifaceted, and effective antitumor immunity, especially when combined with checkpoint inhibition.

Abstract B136: Optimized messenger RNA immunolipoplexes for cancer immunotherapy: Balancing immunogenicity and adjuvancy

Messenger RNA has garnered a lot of attention as a new therapeutic drug class for vaccination (1). Particularly for cancer immunotherapy, mRNA encoding tumor antigens has the potential to design personalized and effective cancer vaccines (2). However, the major challenge remains to directly deliver the mRNA to (professional) antigen presenting cells (APCs), evoking safe and effective antitumor immunity. The mRNA vaccines that are currently being evaluated in first-in-human clinical trials depend on the self-adjuvant effect of mRNA and subsequent signaling via type I IFN (3-4). We and others have reported that type I IFNs have the downside of inducing anti-mRNA (anti-viral) innate responses, which makes it challenging to strike a balance between evoking innate immunity and obtaining adequate levels of mRNA expression (5-6). In addition, high levels of IFN-α are known to cause adverse effects (e.g., flu-like symptoms and autoimmune sequelae) (7).To overcome these issues, we developed a nanoparticle platform which protects mRNA against degradation while successfully delivering mRNA to APCs in vivo (6). In this platform, we choose to minimize the mRNA-based immune recognition using a nucleoside-modified (“immune-silent”) mRNA construct, but instead to co-package clinically-approved immune adjuvants (e.g., MPLA) to achieve strong and controllable immunogenicity. The vaccine potential of mRNA lipid nanoparticles with different immune adjuvants was evaluated by performing biodistribution and immunogenicity studies after systemic delivery in mice. The preclinical antitumor efficacy was assessed in an EG7-OVA lymphoma and B16-OVA melanoma model. In addition to evaluating overall survival, experiments were performed where tumors were isolated after immunization and screened for effector responses (e.g., antigen-specific CD8+ T-cells and NK cells) and suppressive mechanisms that could impact the therapeutic outcome (e.g., immune checkpoints, myeloid derived suppressor cells [MDSCs] and tumor-associated macrophages [TAMs]). To tackle adaptive resistance to activated T-cells, we evaluated a combinatory therapy of the mRNA vaccine with anti-PDL1 antibodies (8). Upon i.v. injection in mice, these particles are mainly detected within APCs (macrophages and dendritic cells) in lungs and spleen. Importantly, this resulted in high mRNA expression as well as functional activation of the particle-loaded immune cells, marked by cytokine production of IL-12p70 and IFN-γ. We were able to optimize a formulation of adjuvanted-nanoparticles with modified mRNA, which resulted in 6 to 7 times higher numbers of tumor-infiltrating antigen-specific T-cells compared to unmodified mRNA particles. In addition to CD8+ T-cell responses, we also observed a 2- to 3-fold increase in intratumoral NK cells, compared to untreated mice. Furthermore, these mice exhibited reduced immune suppression at the tumor site: low numbers of MDSCs whereas TAMs displayed proinflammatory M1-like changes in phenotype. Moreover, we observed clear synergistic antitumor effects between the mRNA nanoparticles and anti-PDL1 checkpoint blocking antibodies. Taken together, we have developed a flexible and versatile mRNA nanoparticle platform, that presents an attractive way of initiating antitumor immunity by targeting and activating immune cells directly in vivo. Importantly, by combining immune-silent mRNA with immune-adjuvants in a single particle, a safe, effective and controllable immune response can be evoked, which can be strengthened by rational combination with state-of-the-art clinically approved immunotherapies. References: 1. Pardi N, et al. Nature Reviews. Drug Discovery 2018. 2. Sahin U, et al. Nature 2017. 3. Kranz L, et al. Nature 2016. 4. Alberer M, et al. Lancet 2017. 5. De Beuckelaer A, et al. Trends in Molecular Medicine 2017. 6. Verbeke R, et al. Journal of Controlled Release 2017. 7. Jonasch E. Oncologist 2001. 8. Sharma P. Cell 2017.

Citation Format: Rein Verbeke, Ine Lentacker, Karine Breckpot, Serge Van Calenbergh, Stefaan C. De Smedt, Heleen Dewitte. Optimized messenger RNA immunolipoplexes for cancer immunotherapy: Balancing immunogenicity and adjuvancy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B136.

Challenges for labeling and longitudinal tracking of adoptively transferred autoreactive T lymphocytes in an experimental type-1 diabetes model

OBJECTIVE

Tracking the autoreactive T-cell migration in the pancreatic region after labeling with fluorinated nanoparticles (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate]-perfluoro-15-crown-5-ether nanoparticles, PDP-PFCE NPs) in a diabetic murine model using ¹⁹F MRI.

MATERIALS AND METHODS

Synthesis of novel PDP-PFCE fluorine tracer was performed for in vitro labeling of T cells. Labeling conditions were optimized using different PDP-PFCE NPs concentrations. For in vivo ¹⁹F MRI, mice were longitudinally followed after adoptive transfer of activated, autoreactive, labeled T cells in NOD.SCID mice.

RESULTS

Established MR protocols were used for challenging T cell labeling to track inflammation in a model of diabetes after successful labeling of CD4+ and CD8+ T cells with PDP-PFCE NPs. However, T cells were difficult to be detected in vivo after their engraftment in animals.

DISCUSSION

We showed successful in vitro labeling of T cells using novel fluorinated liposomal nanoparticles. However, insufficient and slow accumulation of labeled T cells and subsequent T cell proliferation in the pancreatic region remains as limitations of in vivo cell imaging by ¹⁹F MRI.

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

Cancer vaccines based on mRNA are extensively studied. The fragile nature of mRNA has instigated research into carriers that can protect it from ribonucleases and as such enable its systemic use. However, carrier-mediated delivery of mRNA has been linked to production of type I interferon (IFN) that was reported to compromise the effectiveness of mRNA vaccines. In this study, we evaluated a cationic lipid for encapsulation of mRNA. The nanometer-sized, negatively charged lipid mRNA particles (LMPs) efficiently transfected dendritic cells and macrophages in vitro. Furthermore, i.v. delivery of LMPs resulted in rapid expression of the mRNA-encoded protein in spleen and liver, predominantly in CD11c(+) cells and to a minor extent in CD11b(+) cells. Intravenous immunization of mice with LMPs containing ovalbumin, human papilloma virus E7, and tyrosinase-related protein-2 mRNA, either combined or separately, elicited strong antigen-specific T-cell responses. We further showed the production of type I IFNs upon i.v. LMP delivery. Although this decreased the expression of the mRNA-encoded protein, it supported the induction of antigen-specific T-cell responses. These data question the current notion that type I IFNs hamper particle-mediated mRNA vaccines.

Quantitative determination of androstenone in pig adipose tissue

A simple, cheap and rapid method for the quantitative determination of the boar taint substance, 5 alpha-androst-16-en-3-one, in pig adipose tissue is described. After saponification of the fat the androstenone is extracted, derivatised with o-(pentafluorobenzyl)hydroxylamine hydrochloride in pyridine and analysed by fused-silica open-tubular capillary gas chromatography with electron-capture detection.

Metabolism of leucine by the isolated perfused goat udder

Seven lactating goat mammary glands from 6 goats were perfused for several hours in the presence of [U-14C]L-leucine (4 experiments) or [2-3H; 1-14C]DL-leucine (3 experiments) and received adequate quantities of glucose, acetate and amino acids. Radioactivity in casein was mainly recovered in leucine and 90% of casein leucine was derived from free plasma leucine. About 64% of the leucine molecules were used for casein synthesis. Up to 12% of the molecules were channelled into lipid synthesis, while the remaining (up to 24%) were metabolized to CO2. From the 3H/14C ratio of casein and casein leucine, it was calculated that 70-80% of the leucine molecules were reversibly transaminated before their incorporation into milk protein. However, only 4-8% of the plasma leucine molecules were transaminated during passage through the udder. Different pools for oxidation and for protein synthesis may be present in the goat mammary gland.

Sensitive and specific post-column fluorimetric determination of diethylstilboestrol residues in extracts of urine and animal tissues at the 1-ppb level

A rapid method for the selective detection and quantitation of diethylstilboestrol (DES) residues at the 1 ppb level in extracts of urine and animal tissues is described. After selective extraction of the oestrogens, DES is analysed by high-performance liquid chromatography using an in-line specific photochemical reactor followed by oxidation to highly fluorescent products. The reaction products of DES were investigated by thin-layer chromatography (TLC). The specificity of the proposed method was compared with that of a reference TLC method on different extracts of animal origin.

Propionate for fatty acid synthesis by the mammary gland of the lactating goat

Isolated mammary glands of lactating goats were perfused with heparinized and oxygenated blood for 8 to 15 h. Adequate quantities of glucose, acetate, and amino acid were added to the perfusate. After addition of propionate to the perfusion blood, concentrations of odd-numbered and of monomethyl-substituted fatty acids other than those with iso and anteiso configuration increased in the milk fat. These acids seem to be synthesized de novo in the mammary gland. The increase of C17:0 concentration was weak and problematic. We suggest that propionate is acting as a precursor for monomethyl-substituted fatty acids by way of methylmalonyl-CoA. The activating effect of propionate administration upon milk fatty acid production was largest for odd-numbered followed by monomethyl-substituted fatty acids. No increase of iso acids was observed in milk fat in the propionate-infused glands whereas the increase of anteiso acids was extremely small. This agrees with the conception that iso and anteiso fatty acids are synthesized by rumen bacteria.

Sensitive multi-residue method for detection of anabolics in urine and in tisssues of slaughtered animals

A routine procedure is described for the dependable detection of various anabolic residues in tissues or urine contaminated at levels as low as 0.5-10 ppb (10 parts per 10(9)). A suitable extraction and clean-up procedure was developed, permitting adequate recovery (60-80%) of various anabolics from tissue samples (50 g) or urine (50 ml). Following two-dimensional thin-layer chromatography, the presence of the anabolic residues are detected by sulphuric acid-induced fluorescence. The detection limit of most anabolics is of the order of 1-10 ng.

Metabolism of ornithine in perfused goat udder

Four lactating goat mammary glands were perfused for several hours in the presence of ornithine labeled with 1-carbon-14 and delta-nitrogen-15 or 5-hydrogen-3 and received adequate quantities of glucose, acetate, and amino acids. For the first label carbon and nitrogen were incorporated in casein of milk. After isolation of the casein amino acids the carbon-14 was incorporated into proline only while nitrogen-15 was localized in aspartic acid, glutamic acid, alanine, serine, glycine, and the branched-chain amino acids. In the experiments with hydrogen-3 labeled ornithine, no reversible transamination of ornithine could be measured during passage through the udder. After incubation in vitro of goat blood in the presence of the labeled ornithine, no nitrogen-15 could be detected in other free amino acids of plasma. Ornithine is transaminated by the udder itself. The delta-amino group of ornithine contributed nitrogen for the synthesis of several nonessential amino acids in the mammary gland.

Metabolism of [U-14C; 2,3-3H]-L-valine by the isolated perfused goat udder

Two lactating mammary glands excised from 2 goats were perfused for several hours in the presence of [U-14C; 2,3-3H]-L-valine and received adequate quantities of glucose, acetate and amino acids. In the synthesized milk 96 and 89% respectively of the casein valine was derived from free plasma valine. Valine was extensively catabolized by mammary tissue, resulting in a considerable 14CO2 production and in the incorporation of 14C into milk citric acid and to a lesser extent into casein aspartic acid and glutamic acid. About 30% of the valine molecules which were taken up by the mammary gland were oxidized to CO2 and 70% were incorporated in casein as valine residues. About 10% of the plasma valine molecules were reversibly transaminated during one passage through the udder. An important amount of radioactivity of plasma was present in unknown metabolites. Only 7% of this activity was localized in isobutyrate. The radioactivity of total milk fat was very low. Mainly iso-14:0, iso-16:0 and 15:0 were labelled.

Determination of thiocyanate in tissues and body fluids of animals by gas chromatography with electron-capture detection

A method for the quantitative extraction of thiocyanate from biological material has been developed. Levels of 0.2-5 ppm of thiocyanate, in the presence of cyanide, were determined by gas-solid chromatography using 2-bromopropane as internal standard. Reliable results can be obtained only after careful deproteinization of the extracts with hot methanol. Cyanide can be eliminated by reaction with alkaline formaldehyde. The reproducibility of the determination of thiocyanate in biological extracts was +/-5%; the recoveries were over 90%. In vivo experiments with KS14CN-treated rats gave good agreement between the analytical results and the amount of thiocyanate determined by isotope dilution.

Isolation of kallikrein from mammary gland of cows

Small amounts of kallikrein were isolated from bovine mammary tissue. Immediately after slaughter, the udder was removed, perfused with ice-cold xylocaine-Rheomacrodex solution, and homogenized in ice-cold acetic acid solution. Kallikrein-like substances were adsorbed on DEAE-cellulose, eluted with ammonium formate and fractionated by acetone precipitation. The 40-70% acetone fraction was separated on a Shephadex-G 75 column and aliquots of each fraction were incubated for 1 or 2 hr with kininogen. After incubation, extracts were tested for kinin activity on the isolated rat uterus, the rat duodenum, blood flow through the femoral artery of dogs and by intramammary pressure assay in sheep. Release of kinins was demonstrated by all these techniques, highest kallikrein activity being detected in the molecular weight range 50,000 to 60,000. Direct injection of the enzyme into the udder artery of sheep, without prior incubation with kinninogen, resulted in vasodilation and a rise in intramammary pressure. The kallikrein activity was strongly inhibited by aprotinin, but not by soybean trypsin inhibitor or ovomucoid. Kallikrein activity was always associated with esterase activity.

Detection of antithyroid residues in meat and some organs of slaughtered animals

A simple method is described for the routine detection of antithyroid residues in thyroid, liver, kidney and meat contaminated at levels as low as 10 ppb (10 parts per 10(9)). Tissue samples (2 g) are homogenized in methanol, contaminating lipids and amino acids are removed and the antithyroid residues are subjected to reaction with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) in buffer. The NBD derivatives are extracted with diethyl ether and separated by thin-layer chromatography. After spraying with cysteine or mercaptoethylamine, the antithyroid residues appear as fluorescent spots. The detection limit of these compounds is of the order of 200 pg.

Metabolism of (14C)citrulline in the perfused sheep and goat udder

1. A lactating-sheep mammary gland was perfused for 12h in the presence of l-[2-(14)C]-citrulline and received adequate quantities of glucose, acetate and amino acids. Two lactating-goat udders were similarly perfused in the presence of either l-[carbamoyl-(14)C,-2-(14)C]citrulline or l-[carbamoyl-(14)C,1-(14)C]citrulline and l-[4-(3)H]arginine. 2. In these experiments, [(14)C]citrulline was substantially oxidized to CO(2) and converted into arginine and proline of casein. 3. The specific radioactivities of arginine, ornithine and proline of the plasma increased after passage through the udders, demonstrating that [(14)C]citrulline is metabolized by the mammary gland. 4. The presence of two unknown radioactive metabolites of [(14)C]citrulline was detected in the perfusate. These substances were not found after incubation in vitro of oxygenated blood in the presence of the radioactive precursor. 5. From these experiments, it is concluded that citrulline is metabolized in mammary tissue by way of arginine to urea, ornithine and proline.

Variations in the concentrations of free amino acids in the plasma of the dairy cow at parturition

The plasma levels of individual amino acids were studied in 6 dairy cows from 4 days before to 3 days after calving. During this sampling period, the concentrations of 13 amino acids showed significant changes. The levels of several amino acids were depressed markedly in the sample collected immediately before calving. Following parturition, the concentration of most amino acids gradually returned to values obtained 3 days before calving. The glutamine and alanine contents of the plasma rose to a peak value 1 day after calving and subsequently decreased. The mean concentrations of glycine and α-aminobutyric acid did not change before parturition but rose significantly thereafter. These observations are discussed in terms of amino-acid utilization for milk protein synthesis and gluconeogenesis at the onset of lactation. The changes in plasma amino acid levels appear to be synchronized with those reported for prolactin and progesterone in the 24 h before parturition. This may indicate an important influence of both hormones on the lactogenic process in the cow. The highly significant correlations obtained between the concentrations of 14 individual amino acids are discussed.

Metabolism of (U- 14 C)-L-threonine and (U- 14 C)-L-phenylalanine by the isolated perfused udder

A lactating mammary gland of a goat was perfused for 9 h in the presence of [U-14C]-l-threonine and received adequate quantities of glucose, acetate and amino acids. Two lactating sheep udders were likewise perfused in the presence of [U-14C]-l-phenylalanine: the plasma levels of phenylalanine in the first of these experiments were 4 times higher than in the second.

In the [14C]threonine experiment, 4 % of the casein and 0·4 % of the expired CO2were derived from threonine; 85 % of the threonine and 1·6 % of the glycine residues in casein originated from plasma threonine. Small14C levels were found in glutamic acid, aspartic acid and serine of casein. The relative specific activities amongst the casein amino acids and the appearance of appreciable labelling in plasma glycine are consistent with the view that threonine is split by threonine aldolase.

In the [14C]phenylalanine experiments virtually no radioactivity was detected in CO2, lactose or citric acid, indicating that this substrate is not broken down by mammary tissue. In the second experiment, 96 % of the phenylalanine and 0·3 % of the tyrosine of casein originated from plasma phenylalanine. In the first experiment, a 30-fold higher14C incorporation into casein tyrosine relative to phenylalanine was observed. The possible significance of the phenylalanine concentration in the plasma on the degree of conversion of phenylalanine into tyrosine within the mammary gland is discussed.